Abstract
22 patients (mean age 45.08 ± 1.38 years) with essential hypertension stage II were entered in a placebo-controlled blind trial of cilazapril, angiotensin-converting enzyme. A complex of clinical-instrumental tests comprised dipidamol test, bicycle ergometry, 199Tl myocardial scintigraphy, echo-CG. A 3-month course of cilazapril reduced myocardial hypoperfusion in 15 patients, improved left ventricular relaxation. Antiischemia effect of the drug was also evident.
Original language | English |
---|---|
Pages (from-to) | 50-53 |
Number of pages | 4 |
Journal | Terapevticheskii Arkhiv |
Volume | 67 |
Issue number | 9 |
Publication status | Published - 1995 |
Externally published | Yes |
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism